作者: Satish R Raj , Robert S Sheldon
关键词:
摘要: The implantable cardioverter-defibrillator (ICD) has emerged as an effective, but expensive, therapy for arrhythmic sudden cardiac death. ICD use been increasing by 20% to 30% per year. Clinical trials have shown that the can be effective both primary prevention and secondary of death in selected populations. Despite available trial evidence, several issues pertaining remain unresolved, including treatment patients not represented clinical trials, optimal selection who will benefit from ICD, duration quality life with cost-effectiveness cost impact ICD. These considerations are discussed this article.